_1576845297366.png?format=webp&height=120&width=120){kind=logo}
About Sherpa Venture Capital
Sherpa Venture Capital is a venture capital firm founded in 2018. It is primarily based out of Beijing, China. As of Feb 2026, Sherpa Venture Capital is an active investor, having invested in 18 companies, with 1 new investment in the last 12 months. It primarily invests in Series B round in China based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series A round of Avisi Technologies Overall, Sherpa Venture Capital portfolio has seen 4 IPOs including key companies like Cytek Biosciences, Insight Lifetech and VISEN Pharmaceuticals. A lot of funds co-invest with Sherpa Venture Capital, with names like Sequoia Capital China sharing a substantial percentage of its portfolio. Sherpa Venture Capital has team of 6 people including 4 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Seed & 3 more
Portfolio IPOs
Portfolio Soonicorns
Deals in last 12 months
Sherpa Venture Capital's List of Top Investments
Sherpa Venture Capital has a portfolio of 18 companies. Their most notable investments are in Singleron and Xisoft Technology.Their portfolio spans across China, United States and Germany. They have invested in Life Sciences, High Tech, HealthTech and 3 other sectors, across stages such as Series B, Seed and 3 more. Here is the list of top investments by Sherpa Venture Capital:Manufacturer of flow cytometry systems for research applications. The company's flagship product is the DxP Athena flow cytometer which can be configured for detection of colors with lasers. The systems can also be equipped with liquid handling components for automatic micro-sampling, and fluid management system.
Key facts about Cytek Biosciences
- Founded Year: 2014
- Location: San Francisco (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $144M
- Employee Count: 445 as on May 31, 2026
- Investors: HTIF, Orbimed and 12 Others
- Latest Funding Round: Series D, Nov 05, 2020, $*****
- Highlight: Public
Developer of nano-materials. It provides users with a platform that develops an ultrathin nanoplate made of alumina, implant material is developed in collaboration with the University of Pennsylvania for treating mid to late-stage glaucoma.
Key facts about Avisi Technologies
- Founded Year: 2017
- Location: Philadelphia (United States)
- Stage: Series A
- Total Funding till date: $15.7M
- Employee Count: 19 as on May 31, 2026
- Investors: MedVenture Partners, Good Growth Capital and 21 Others
- Latest Funding Round: Series A, Feb 25, 2026, $*****
- Highlight: Editors' Pick
Insight Lifetech is developing medical devices for precision diagnosis of coronary diseases. Its device, TruePhysioTM Microcatheter provides hemodynamic information for the diagnosis and treatment of coronary and peripheral artery diseases. The device is an application in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
Key facts about Insight Lifetech
- Founded Year: 2015
- Location: Shenzhen (China)
- Stage: Public
- Total Funding till date: $42.7M
- Employee Count: 45 as on May 31, 2026
- Investors: Decheng Capital, SDIC Chuanghe Fund Management and 9 Others
- Latest Funding Round: Series C, Dec 31, 2020, $*****
- Highlight: Public
4. EdiGene
Developer of genome editing technology for the treatment of cancer and genetic disease. The company has developed LEAPER technology, which is an in vivo oligonucleotide-based RNA single-base editing technology used for the treatment of Hurler syndrome. The company's in vitro therapy includes ET-01 for β-thalassemia major and the allogeneic CAR-T ET-02 for cancer.
Key facts about EdiGene
- Founded Year: 2015
- Location: Changping District (China)
- Stage: Series B
- Total Funding till date: $165M
- Employee Count: 51 - 200 as on Jul 01, 2024
- Investors: 3H Health Investment, Loayal Valley Capital and 16 Others
- Latest Funding Round: Series B, Apr 21, 2021, $*****
- Highlight: Editors' Pick
EpimAb Biotherapeutics is a privately owned R&D company focussed on developing bispecific antibody therapeutics with its proprietary technology called FIT-Ig (Fabs-In-Tandem Immunoglobulin). The technology re-arranges the DNA sequences of two MAbs into three constructs and co-expressing them in mammalian cells, it generates bi-specific FIT-Igs that fully retain the biological function of their parental MAbs.It is currently creating a pipeline of its own bispecific antibody therapeutics focused around immuno-oncology. It has collaboration with Innovent Biologics to develop Multi-Target Bispecific Antibody. Their lead candidate is EMB-01 a bispecific antibody based on EpimAb’s proprietary platform FIT-Ig, which according to company claims has shown promising results in multiple preclinical cancer models.
Key facts about EpimAb Biotherapeutics
- Founded Year: 2015
- Location: Shanghai (China)
- Stage: Series C
- Total Funding till date: $219M
- Investors: Cormorant Asset Management, Mirae Asset and 14 Others
- Latest Funding Round: Series C, Mar 22, 2021, $*****
- Highlight: Editors' Pick
Sherpa Venture Capital's Year-on-Year Investment Trends
Sherpa Venture Capital has invested in 18 companies over the last 8 years, with an average of 0 new investment annually in the last 5 years. As of Feb 2026, it has made 1 investment in this year. Its most recent first time investment was in Avisi Technologies and most recent follow-on round was in Huida.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 |
2022 | 1 | 1 | 2 |
2021 | 3 | 0 | 3 |
2020 | 2 | 2 | 4 |
2019 | 6 | 1 | 7 |
2018 | 2 | 0 | 2 |
Sherpa Venture Capital's Investments by Stage
Sherpa Venture Capital has made 7 investments in Series B stage with an average round size of $57M, 3 investments in Seed stage with an average round size of $9.4M, 3 investments in Series A stage with an average round size of $15.4M, 1 investment in Series C stage with an average round size of $45M and 1 investment in Series D stage with an average round size of $400M.Stage of entry | No. of Investments |
|---|---|
Series B | 7 |
Seed | 3 |
Series A | 3 |
Series C | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
Sherpa Venture Capital's Investments by Sector
Sherpa Venture Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Healthcare and Chemicals and Materials Tech. Notably, it has invested in 13 Tech companies, 11 Enterprise (B2B) companies, 2 Software companies and 2 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 12 |
High Tech | 5 |
HealthTech | 2 |
Healthcare | 2 |
Chemicals and Materials Tech | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
Sherpa Venture Capital's Investments by Geography
Sherpa Venture Capital has made most investments in China (12), followed by United States where it has made 2 investments.Country | No. of Investments |
|---|---|
China | 12 |
United States | 2 |
Germany | 1 |
Note: We have considered here, only first round of investments
Sherpa Venture Capital's recent investments
Sherpa Venture Capital has made 1 investments in 2026 so far - Avisi Technologies.Here are the most recent investments by Sherpa Venture Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Feb 25, 2026 | United States | Series A | 8085 | [+8] | |
May 12, 2022 | China | Series C | 1714 | [+1] | |
Feb 11, 2022 | China | Series D | 4457 | ||
Apr 21, 2021 | China | Series B | 8804 | ||
Apr 19, 2021 | United States | Series B | 8987 | [+5] |
IPOs and Publicly Listed companies in Sherpa Venture Capital's Portfolio
4 of Sherpa Venture Capital's portfolio companies have become public. Insight Lifetech got listed on the Shanghai Stock Exchange (SSE), in Feb 2026 and VISEN Pharmaceuticals got listed on the Hong Kong Exchanges (HKG) at marketcap of $1.01B.Here are Sherpa Venture Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 05, 2026 | 2018 | Series B | 5887 | |
Mar 21, 2025 | Jan 08, 2021 | Series B | 9385 | |
Aug 20, 2021 | - | - | 4305 | |
Jul 23, 2021 | - | - | 1607 |
Team profile of Sherpa Venture Capital
Sherpa Venture Capital has a team of 6 members including 4 Partners and 2 Venture Partners located in China and United States. Sherpa Venture Capital's team does not sit on the board of any company as of now.Here is a list of all team members in Sherpa Venture Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Xuhui | - | - | |
Partner | China | - | - | |
Partner | China | - | ||
Partner | China | - | ||
Venture Partner | Irvine | - | ||
Venture Partner | Cambridge | - |
Co-investors of Sherpa Venture Capital
Over the past 8 years, 112 investors have co-invested in Sherpa Venture Capital's portfolio companies. This includes funds and angels.
- Invested before Sherpa Venture Capital: Yuanhe Holdings, MedTech Innovator and 29 others have invested in rounds before Sherpa Venture Capital. There are 2 companies where Yuanhe Holdings has invested before Sherpa Venture Capital and 1 company where MedTech Innovator has invested before Sherpa Venture Capital.
- Top Co-investors of Sherpa Venture Capital: 41 investors entered a company along with Sherpa Venture Capital. These include investors like Sequoia Capital China (2 companies).
- Invested after Sherpa Venture Capital: A total of 40 investors have invested in Sherpa Venture Capital's portfolio after their investments. Top Investors include Sherpa Healthcare Partners (4 companies), SDIC (1 company) and Green Pine Capital Partners (1 company).
Recent News related to Sherpa Venture Capital
•
Avisi Technologies Raises $10.7M in Series A FundingFinSMEs•Feb 25, 2026•OneOneFive, Accanto Partners, Gemseki, Sherpa Venture Capital and 7 others
•
EdiGene finishes successful round of financingChina Daily•Apr 21, 2021•3H Health Investment, EdiGene, Sequoia Capital, Sherpa Venture Capital and 6 others
•
•
•
EpimAb reels in $120M to propel 3 clinical-stage bispecifics, including dual checkpoint inhibitorFierce Biotech•Mar 22, 2021•EpimAb Biotherapeutics, Cormorant Asset Management, Yanchuang Capital, ShangBay Capital and 6 others
•
VISEN Pharmaceuticals closes $150 million Series B financingIndiaMedToday•Jan 11, 2021•VISEN Pharmaceuticals, Sequoia Capital, Orbimed, Sherpa Venture Capital and 8 others
•
Sequoia China leads $150m series B round for Chinese biotech firm VisenTech in Asia•Jan 11, 2021•VISEN Pharmaceuticals, Sequoia Capital, Orbimed, HBM Healthcare Investments and 8 others
•
•
•
Aiming at the field of valvular heart disease, this company has raised hundreds of millions to focus on the research and development of heart valve interventional devicesPencilNews•Nov 27, 2020•Kekai (Nantong) Life Science, ZSVC, Shenzhen Guozhong Venture Capital Management, Volcanics Venture and 4 others
